EC
RPTX

EntryPoint Capital’s Repare Therapeutics RPTX Stock Holding History

EntryPoint Capital’s Portfolio RPTX Stock Details RPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,005
Closed -$4.73K – 1516
2024
Q1 		$4.73K Buy
+1,005
New +$6.44K ﹤0.01% 1303

Other funds holding RPTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

EntryPoint Capital's RPTX Position: Q2 2024 in Review

EntryPoint Capital sold out of Repare Therapeutics (RPTX) in Q2 2024, closing a stake of 1,005 shares — an estimated $4.73K sold.

EntryPoint Capital first reported a position in RPTX in Q1 2024 and held it in 1 quarter. The position peaked at $4.73K in Q1 2024. 61 funds tracked by Wall St. Rank hold RPTX as of Q2 2024.

  • EntryPoint Capital reported no remaining Repare Therapeutics position as of Q2 2024 after selling out during the quarter.
  • EntryPoint Capital sold 1,005 Repare Therapeutics shares in Q2 2024, an estimated $4.73K.
  • EntryPoint Capital first reported a position in Repare Therapeutics in Q1 2024 and held it in 1 quarter.
  • EntryPoint Capital's Repare Therapeutics position peaked at $4.73K in Q1 2024.
  • 61 funds tracked by Wall St. Rank held Repare Therapeutics as of Q2 2024.

Based on EntryPoint Capital's 13F filing for Q2 2024, filed 13 Aug 2024.